



kinderkrebsinfo.de

Informationsportal zu Krebs- und Bluterkrankungen bei Kindern und Jugendlichen

High-Grade Glioma (HGG) – Brief Information

Copyright © 2024 Competence Network Paediatric Oncology and Haematology

Author: Maria Yiallourous, created 2007/03/09, Editor: Maria Yiallourous, Release: Prof. Dr. med.

Christof Kramm, English Translation: Dr. med. Gesche Riabowol (nee Tallen), Last modified:

2024/03/21

Kinderkrebsinfo is sponsored by Deutsche Kinderkrebsstiftung





Table of Content

1. General information on the disease	3
2. Incidence	3
3. Types of high-grade gliomas	3
4. Causes	4
5. Symptoms	5
5.1. General (unspecific) symptoms	5
5.2. Local (specific) symptoms	5
6. Diagnosis	5
6.1. Tests to secure diagnosis	6
6.2. Tests before treatment begins	6
7. Treatment planning	7
8. Treatment	8
8.1. Treatment methods	8
8.2. Course of treatment (standard therapy for patients from 3 years of age)	9
8.2.1. Induction phase	9
8.2.2. Consolidation phase	9
8.2.3. Treatment options after this therapy	10
9. Therapy optimising trials	10
10. Treatment according to therapy optimising trial HIT-HGG 2013	11
11. Prognosis	12
Bibliography	13
Glossary	16

High-Grade Glioma (HGG) – Brief Information

1. General information on the disease

Highly malignant or high-grade gliomas (HGG) are *tumours* of the *central nervous system* (CNS). They are *solid tumours* arising from transformed cells of the *brain* and/or the *spinal cord*. Since they directly originate from the central nervous system, they are also called primary CNS tumours, thereby differentiating them from malignant tumours of other organs that have spread (metastasised) to the CNS.

High-grade gliomas in children and adolescents are rare. However, they show considerably malignant behaviour since they usually grow fast and frequently destroy healthy brain tissue. By being able to migrate within the central nervous system for various centimetres, high-grade gliomas can induce the development of new tumours. Without the appropriate therapy, high-grade gliomas can be lethal within only a few months. Due to their usually rapid and infiltrating growth, treatment is difficult.

2. Incidence

High-grade gliomas account for approximately 15 to 20 % of *CNS tumours* in children and adolescents. They appear in all age groups; yet, children aged younger than three years are rarely affected. Each year, about 60 to 80 children and adolescents younger than 15 years of age are newly diagnosed with a high-grade glioma in Germany. This corresponds to an incidence rate of 5 to 10 new diagnoses per 1.000.000 children per year. Boys and girls are almost equally affected.

3. Types of high-grade gliomas

Various types of high-grade gliomas (HGG) have been identified based on their localization within the central nervous system (CNS), the cell of origin and the degree of malignancy.

High-grade gliomas of the brainstem

High-grade gliomas of the *brainstem*, such as "typical diffuse intrinsic pontine glioma" (as well as *histologically* and *genetically* diagnosed "diffuse midline gliomas HR K27M mutated WHO-grade IV", as long as they are located in the brainstem), account for about one third of all HGG in children and teenagers. Due to their localization within the pons – an area of the brainstem, through which all important nerve tracts between extremities and brain are passing –, they can cause various severe *neurological* deficits and also result in a rapid and fatal course of the disease, even when they are small in size.

Gliomas in other parts of the central nervous system



About two thirds of high-grade gliomas are usually found in other parts of the CNS, especially in the cerebral cortex [see *cerebrum*]. These gliomas can be further subgrouped based on their histological and *molecular* characteristics, which provide insight into their origin and degree of malignancy. In general, these are tumours that are classified as WHO-grade III or WHO-grade IV according to the grading system of the World Health Organization (*WHO classification*).

In children and adolescents, the most common among HGG are anaplastic *astrocytomas* (WHO grade III) and *glioblastoma* multiforme (WHO grade IV). Other tumour types are rather rare. These include the gliomatosis cerebri, a type of tumour that is typically characterised by a particularly extended infiltration and spread into adjacent tissue. Although its cells are frequently of low-grade malignancy, this tumour is classified as a highly malignant glioma because of its distinct growth pattern.

Good to know: The various types of HGG differ in frequency and show different growth characteristics, different courses of the disease, different responses to treatment, and thus different outcomes (prognoses).

Note with regards to typical diffuse intrinsic pons glioma (DIPG): DIPG, which are usually diagnosed by imaging, frequently turn out as "diffuse midline gliomas histone 3 K27M-mutated (WHO-grade III)" based on their histology and molecular biological characteristics and are, therefore, classified by the WHO as an entity of their own. However, despite their different terminology based on underlying diagnostics, they represent the same tumour type after all.

4. Causes

High-grade gliomas originate from a malignant transformation of *glial cells* (glia). These are cells that, among other functions, provide support and protection for the brain's nerve cells (neurons). Why glia cells become malignant in some individuals is not completely known yet.

It is known so far that children with certain inherited diseases (such as *Li-Fraumeni syndrome* or *Turcot syndrome*) have a higher risk of developing high-grade gliomas than their healthy peers. Because these genetic conditions are associated with an elevated risk for tumour development, they are also known as *cancer predisposition syndromes*. In addition, it has been shown that malignant glial cell transformation can be associated with genetic alterations and/or chromosomal aberrations in these cells. In general, these genetic alterations in tumor tissue are not relatively and most certainly developed early in development.

Also, *radiation* of the skull (cranial irradiation), for example during treatment of *leukaemia* or *retinoblastoma*, a malignant tumour of the eye, increases the risk of developing a CNS tumour. Although not as frequently, *chemotherapy* can also promote the development of a high-grade glioma. However, for most children and adolescents, no specific cause for the development of high-grade glioma has been identified so far.

5. Symptoms

Due to the tumours' rapid growth, *symptoms* of children and adolescents with high-grade glioma usually develop within a few weeks or months. Similar to those of other *CNS tumours*, the presenting symptoms of high-grade gliomas primarily depend on the patient's age, tumour site and size, and pattern of spread within the *central nervous system*. The following general (nonspecific) and local (specific) symptoms can occur.

5.1. General (unspecific) symptoms

Unspecific general symptoms occur independently of the tumour's location. They may be similar to and therefore mimic other, non-CNS diseases. General symptoms of a child or adolescent with a CNS tumour may include headaches and/or back pain, dizziness, loss of appetite, nausea and vomiting (particularly after getting up in the morning), weight loss, increasing fatigue, inability to concentrate, school problems, mood swings, and character changes as well as developmental delay, to name a few.

Major reason for these symptoms is the slowly but continuously increasing intracranial pressure (ICP). Elevated intracranial pressure may be caused by the growing, thus more and more space-occupying tumour within the bony skull (or spinal canal), but also by the tumour blocking the regular flow of the *cerebrospinal fluid*, thereby forming *hydrocephalus*. In babies or small children with soft spots (open *fontanelles*), elevated intracranial pressure and hydrocephalus typically present with a bulging fontanelle or a larger than expected head circumference (*macrocephalus*), respectively.

5.2. Local (specific) symptoms

Local symptoms may indicate the tumour location, thus, which functional regions of the central nervous system may be affected. Thus, a high-grade glioma in the *cerebellum* can cause dizziness and gait disturbances, whereas such a tumour in the hemispheres (*cerebrum*) can be associated with *seizures*, and a tumour of the *spinal cord* with different kinds of motor and sensory deficits (like muscle weakness and numbness), to name a few. Also, impaired vision or mental and sleep problems may be indicative of tumour location.

Good to know: Not all patients presenting with one or more of the symptoms mentioned above do have a high-grade glioma or another type of brain tumour. Many of these symptoms may also occur with other, harmless diseases that are not associated with a brain tumour at all. However, if certain symptoms persist or get worse (for example repetitive headaches or rapid increase of head circumference in a young child), a doctor should be seen to find the underlying reason. In case it is a brain tumour, treatment should be started as soon as possible.

6. Diagnosis

If the paediatrician thinks that the young patient's history (*anamnesis*), *physical examination* and possibly even results from diagnostic *imaging* are suspicious of a tumour of the central nervous system (CNS), the child should immediately be referred to a hospital with a childhood cancer

program (paediatric oncology unit), where further diagnostics can be initiated and performed by childhood cancer professionals. Very close collaboration between various specialists (such as *paediatric oncologists*, paediatric neurosurgeons, paediatric *radiologists*, to name a few) is required, both to find out, whether the patient really suffers from a malignant CNS tumour and, if so, to determine the tumour type and the extension of the disease. Knowing these details is absolutely essential for optimal treatment planning and *prognosis*.

6.1. Tests to secure diagnosis

The initial diagnostic procedures for a young patient presenting with a suspected CNS tumour at a childhood cancer centre include another assessment of the patient's history, a thorough physical/*neurological* exam and imaging diagnostic, such as *magnetic resonance imaging* (MRI) or (less often) *computed tomography* (CT). These tests help find out exactly whether the patient has a tumour of the central nervous system. Also, localisation and extent of the tumor, its demarcation regarding adjacent tissue as well as a potential *hydrocephalus* can be diagnosed by these imaging techniques very well.

In children with a suspected tumour of the visual tract, an assessment by an experienced eye specialist (ophthalmologist) is also performed. Depending on the patient's individual situation with regards to disease and treatment, additional tests may be required. For example, investigation of the cerebral spinal fluid, gained by *lumbar puncture*, might be needed in order to identify or rule out, respectively, a spread of tumour cells into the spinal canal.

For most patients, final diagnosis is backed up by microscopic (histological) examination of tumour tissue that has been neurosurgically removed (*biopsy*). An exception, however, are children with gliomas of the *brainstem* (pontine glioma) or gliomatosis cerebri, respectively, diagnosis of which can usually be confirmed based on typical MRI characteristics and clinical symptoms. An additional biopsy may contribute to a better characterisation of these tumours and may therefore be recommendable, but not ultimately required for treatment planning.

6.2. Tests before treatment begins

In preparation for the intensive treatment of the brain tumour, further investigations are performed, such as *electrocardiography* (ECG) and *echocardiography* to check cardio function. An *electroencephalography* (EEG) helps identify potential areas in the brain that the tumour might have made susceptible to cause *seizures*. In addition, an *ophthalmological* exam as well as various electrophysiological investigations to assess vision, hearing, motor and sensory functions (*evoked potentials*) may be required.

Furthermore, additional blood tests are needed to assess the patient's general health condition and to check whether the function of certain organs (such as liver and kidneys) is affected by the disease and whether there are any metabolic disorders to be considered prior or during therapy. Condition and function of the hormonal glands will be checked in order to detect and manage potential tumour- and/or treatment-associated endocrinological impairments as early as possible. For the same reason, neuropsychological testing might be done prior to cancer treatment. Any changes occurring during the course of treatment can be assessed and managed better based on



the results of those initial tests, which thus help to keep the risk of certain treatment-related side effects as low as possible.

Also, the patient's *blood group* needs to be determined in case a *blood transfusion* is required during treatment. In sexually mature females (which means after they have experienced their first menstrual bleeding), a pregnancy test is recommended prior to treatment as well.

Good to know: Not every patient needs the complete check-up. On the other hand, tests might be added that haven't been mentioned here, depending on the individual situation of the patient. Your caregivers will inform you and your child, which diagnostic procedures are individually required in your case and why.

Psychosocial Care

A child's cancer is a stressful situation for the whole family. The psychosocial team of the clinic or later the aftercare facility provides advice and support to patients and their relatives from diagnosis to completion of treatment as well as during aftercare. Don't hesitate to take advantage of this offer. It is an integral part of the treatment concept of all paediatric oncology centres in many countries. Here you will find comprehensive information on this.

7. Treatment planning

Once the diagnosis of a malignant glioma has been confirmed, treatment planning starts. In order to provide the patient with the best possible individual and risk-adapted therapy, the treatment team considers specific factors that are known to have an impact on the *prognosis* (so-called prognostic factors).

Important *prognostic factors* are the type of malignant glioma, its size, localization, and spread in the central nervous system. Detailed knowledge about the type of tumour allows conclusions regarding its growth pattern and grade of malignancy (WHO-grade, see chapter "*Types of malignant gliomas*"), whereas the tumour site and size determine its *operability*. Both factors have immediate impact on the patient's chances of survival and, therefore, are a major basis when choosing the optimal treatment strategy. Additionally, response to treatment, age and the patient's health status at the time point of diagnosis play an important role.

All these risk factors are considered when planning the treatment. The goal is to achieve the best possible results for every patient. Hence, the individual disease situation determines how the patient should be treated best.

Patients (at the age of three or older) who have been diagnosed with a high-grade glioma [such as glioblastoma multiforme WHO-grade IV (GBM), diffuse midline glioma histone 3K 27M-mutated WHO-grade IV (DMG), anaplastic astrocytoma WHO-grade III (AA), diffuse intrinsic pons glioma (DIPG), and gliomatosis cerebri (GC)] receive an intensive treatment, usually in the framework of a therapy optimising study (see chapter "*Treatment*" and "*Therapy optimising trials*").

The treatment plans for patients with less frequent grade III gliomas (such as anaplastic oligodendroglioma, anaplastic oligoastrocytoma, anaplastic ganglioglioma, or anaplastic pleomorphic xanthoastrocytoma) usually include a less intensive therapy due to the relatively



favourable prognosis of these tumours. Children under the age of three years are treated as per so-called infant protocol, which does not include radiotherapy.

8. Treatment

If high-grade glioma has been diagnosed, treatment should be started as soon as possible in a children's hospital with a paediatric oncology program. Only in such a treatment centre, highly experienced and qualified staff (doctors, nurses and many more) is guaranteed, since they are specialized and focus on the diagnostics and treatment of children and teenagers with cancer according to the most advanced treatment concepts. The doctors in these centres collaborate closely with each other. Together, they treat their patients according to treatment plans (protocols) that are continuously optimised. The goal of the treatment is to achieve high cure rates while avoiding acute or long-term side effects as much as possible.

Treatment strategies for patients with high-grade glioma include **surgical tumour removal** as well as **radiotherapy** and **chemotherapy**. The choice of treatment strategy depends primarily on the site and extent of the tumour (thus, its removability) as well as on the patient's age at diagnosis and the individual health situation.

8.1. Treatment methods

The most effective treatment for children and adolescents with high-grade glioma is a combination of *neurosurgery*, *radiation therapy*, and *chemotherapy*. Neurosurgery is performed first, followed by chemo- and radiotherapy, which are usually applied during the same phase of treatment (simultaneously). Neurosurgery is of highest impact, since the extent of tumour removal significantly determines the further course of the disease. The more radically the tumour can be resected, the higher are the chances of survival. According to the current standard of knowledge, surgery and radiation have proven to extend the life span of a young patient with high-grade glioma.

Yet, surgery or radiation cannot be performed in every child. Many tumours of the *brainstem*, such as diffuse intrinsic pontine gliomas, are neurosurgically not accessible. Also, radiotherapy of the brain or spinal cord is not recommended for children aged younger than three years. In addition, the possible, still justifiable extent of tumour removal can vary: tumours that are located very centrally in the brain (for example tumours of the *diencephalon* or the *midbrain*) usually cannot be completely removed or approached surgically at all, since this would result in a substantial damage of healthy brain tissue and associated deficits.

Previous therapy trials have shown that additional (adjuvant) chemotherapy can improve treatment results. However, no treatment approach ensuring that the tumour will not start growing again after a short while has been developed so far. The most crucial step prior to any treatment is the decision whether the patient should receive therapy, and if so, which goal the treatment should have: either cure (curative treatment) or management of disease-related symptoms, such as pain (*palliative therapy*). Regardless of the goal setting, treatment and care in the framework of a trial is always recommended.

8.2. Course of treatment (standard therapy for patients from 3 years of age)

The following paragraphs introduce the current recommendations for standard therapy for children and adolescents (from 3 years of age) with high-grade glioma (grade-IV glioma, anaplastic glioma grade III, pontine glioma, gliomatosis cerebri). Treatment recommendation for children younger than three years of age is different, in particular, it doesn't include radiotherapy. Information on treatment as per therapy optimising study "HIT-HGG 2013", which has been open for recruitment since spring 2018, can be found in the chapter „Treatment according to trial HIT-HGG 2013“.

First step when treating a patient with high-grade glioma is maximal neurosurgical tumour removal, with the exception of pontine glioma and gliomatosis cerebri, which are surgically not accessible due to their localisation or growth pattern, respectively.

Surgery is followed by radiotherapy and chemotherapy, which are also recommended for patients with inoperable tumours. Treatment consists of two major parts: the induction phase at the beginning (induction therapy) and the subsequent consolidation phase (consolidation therapy). Both phases include various treatment blocks.

8.2.1. Induction phase

Induction therapy starts about two to four weeks after surgery or directly after an MRI-based diagnosis, respectively. It takes six to seven weeks and either aims at further reducing the size of a tumour that could not be completely removed or at eliminating potentially remaining tumour cells after complete tumour removal. The major approach includes simultaneous radio- and chemotherapy.

Radiotherapy (*radiation therapy*) is given through the skin to the tumour region over a period of six to seven weeks with daily doses of 1.8 *gray* (Gy). The total radiation dose depends on the patient's age and the site of the tumour: For children between three and five years of age, the total dose is 54 Gy, for children from the age of six it is 59.4 Gy. For patients with glioma of the brainstem (pontine glioma), limitation of the total dose to 54 Gy is recommended. Radiotherapy is given five days a week, sparing the weekends.

Chemotherapy includes treatment with the agent temozolomide (Temodal®), which is taken as a pill every evening from day one to the last day of radiation. This also applies to weekends, although there is no radiotherapy on weekends. Radiotherapy and simultaneous *chemotherapy* are followed by a four weeks' break. This gives the patient some time to recover before consolidation phase starts.

8.2.2. Consolidation phase

Consolidation therapy begins about four weeks after cessation of induction, that means, after the recovery phase. Consolidation consists of chemotherapy only and takes about a year. Its goal is to maintain the results achieved by induction treatment or to even improve them.

For chemotherapy, temozolomide is given again, but with its dosage usually twice as high compared to induction therapy. If tolerated well, it can even be increased further. Treatment is given for five days in a row, followed by a 23 day recovery phase. This results in a repetition of treatment every 28 days (four weeks) for a total of 12 courses. The efficacy of treatment is monitored by regular *MRI* controls.

8.2.3. Treatment options after this therapy

In some patients, the tumour size shrinks, thereby becoming surgically accessible and possibly completely removable after induction, or after both induction and consolidation therapy, respectively. Other patients suffer progressive disease despite treatment and, thus, may not benefit from standard therapy any more. Depending on their individual situation, treatment recommendations focusing on progressive or recurrent disease may be considered for subsequent management.

9. Therapy optimising trials

In the large paediatric treatment centres, diagnostics and therapy of almost all children and adolescents with high-grade glioma (HGG) are performed according to standardised treatment plans (protocols), which aim at continuously increasing the probability of survival for these patients. Treatment as per these protocols is usually done within the framework of controlled, multicentre “*therapy optimising trials*”. The treatment concepts of such trials are continuously being optimised based on the latest medical knowledge and the experience with former protocols.

In Germany (with international participation), the following therapy optimising trials or treatment recommendations, respectively, are currently active for patients with malignant glioma, pontine glioma or with gliomatosis cerebri:

- **Trial HIT-HGG 2013:** Since July 2018, children and adolescents between the age of 3 to 17 years who have been newly diagnosed with high-grade glioma (grade-IV glioma, anaplastic astrocytoma grade III), pontine glioma or gliomatosis cerebri, can be recruited into this trial. HIT-HGG 2013 represents the subsequent study of the HIT-HGG 2007 trial, which was closed for recruitment by the end of 2016 and is currently being analysed. Numerous childhood cancer centres throughout Germany, Switzerland, Austria, and Belgium participate in this trial. The German trial centre is located at the Department of Paediatric Oncology/Haematology, University Hospital Göttingen (principal investigator: Prof. Dr. med. Christof Kramm). **Please note:** as from the end of 2023 no further patients are admitted to the trial!
- **Therapy recommendations for infants according to the future trial HIT-SKK:** Infants and toddlers (aged younger than three years at diagnosis, which is rare), are currently treated according to the recommendations which will form part of the future trial for infants, HIT-SKK (treatment without radiotherapy). A proposal for a separate registry has been submitted (see *below*). Treatment according to the future registry will be based on the recommendations given in the HIT-SKK protocol. The registry centre will stay at the University Hospital Göttingen, supervised by Prof. Dr. med Christof Kramm.

- **Trial HIT-HGG-REZ-Immunovac:** Since February 2018, patients with relapsed high-grade glioma can be recruited to the trial HIT-HGG-REZ-Immunovac. This study investigates whether giving a vaccine after relapse surgery improves patient survival (immunotherapy). The trial is currently active in one German treatment centre (University Children's Hospitals in Würzburg) with Prof. Dr. med. Matthias Eyrich (Universitätsklinik Würzburg) as the principal investigator.

Future registry: For 2022, the opening of a registry is planned for children under three years of age as well as for all patients who won't receive treatment as per trial HIT-HGG 2013. The latter include, for example, children and adolescents with the less frequent grade-III tumours (such as anaplastic oligodendroglioma, anaplastic oligoastrocytoma, anaplastic ganglioglioma, anaplastic xanthoastrocytoma). For this registry, the study centre will also offer treatment recommendations based on the most recent scientific knowledge. Hence, the spectrum of recommendations provided by the trial centre will consider patients of all age groups, regardless of their diagnosis.

10. Treatment according to therapy optimising trial HIT-HGG 2013

Please note: Since the end of 2023, no further patients have been admitted to the trial!

Treatment according to trial HIT-HGG 2013 is based on the current standard therapy, which consists of neurosurgical tumour removal (if applicable) followed by a combined radio-/chemotherapy (with temozolomide). This strategy was previously introduced to children and adolescents in trial HIT-HGG 2007, and its efficacy has proven to be comparable to that achieved by conventional multi-agent chemotherapy regimens, but with less treatment-induced adverse effects and long-term secondary damages (sequelae).

Since overall treatment results for patients with high-grade glioma (including pontine glioma and gliomatosis cerebri) are still unsatisfactory, the new trial was initially designed to test two new agents in addition to the standard regimen and compare their efficacy by conducting a trial with two treatment "arms": one of them using valproic acid, which is also used as an anti-epileptic drug [see *epilepsy*], the other one chloroquin, which is known as an anti-malaria agent. As indicated, both substances have been used to treat other diseases over decades, but have most recently also shown anti-tumour effects. Patients were assigned to the two different trial arms in a randomised manner. Unfortunately, the use of chloroquin was ceased in July 2019. Therefore, the chloroquin arm in the trial was closed, while treatment with valproic acid has been continued. Randomisation [see *randomisation*] has become redundant since.

The trial is supposed to find out whether the additional agent significantly improves the efficacy of the current radio- and chemotherapy and, thus, probability of survival.

Treatment with valproic acid starts as soon as possible, which means immediately after confirmation of diagnosis (either histologically after surgery, or, if surgery is not an option, immediately after confirming diagnosis by MRI). The agent is given as pills or suspension on a daily basis, without any break, over a total of 58 weeks (or longer).

About two to four weeks after histological or radiological diagnosis (defined as week 0), standard therapy begins, comprising radiotherapy and simultaneous chemotherapy with temozolomide for six to seven weeks (induction therapy) and a subsequent treatment phase with temozolomide alone for about a year (consolidation therapy). *Information on standard therapy is provided in chapter "Course of treatment (standard therapy for patients from 3 years of age)".*

11. Prognosis

Despite improved methods in diagnosis and therapy, *prognosis* for children and adolescents with high-grade glioma is still unfavourable. The overall probability to survive 5 years after the initial diagnosis was made is currently about 10 to 19 %. However, overall survival rates significantly depend on the localization and type of high-grade glioma as well as on the extent of tumour removal by surgery. Therefore, they may vary between 50 % for patients after complete resection and 0 % for those children for whom no anticancer therapy is possible at all.

In general, the possibility to develop recurrent disease (*recurrence*, relapse) after successful first-line treatment is high for young patients with a high-grade glioma and prognosis for patients with relapsed disease is even worse. A new treatment approach has to be considered carefully to maintain appropriate quality of life for the patient. Current *therapy optimising trials* aim at further improving the treatment options and reducing the side effects for patients with childhood (relapsed) HGG. Further specific knowledge of the disease is intensified by associated research projects, the results of which will determine future treatment protocols.

Note: The survival rates mentioned in the text above are statistical values. Therefore, they only provide information on the total cohort of patients with childhood high-grade gliomas. They do not predict individual outcomes. High-grade gliomas can show unpredictable courses, in both patients with favourable and patients with unfavourable preconditions.

In the context of cancer, the term „cure“ should rather be referred to as „free of cancer“, because current treatment regimens may help to destroy the tumour, but they are also frequently associated with numerous late-effects. Early detection and appropriate management of these long-term secondary effects typically require intensive rehabilitation and thorough long-term follow-up care, although a patient may have been „cured“ from the cancer.

Bibliography

- [1] Broniscer A, Gajjar A „, Supratentorial high-grade astrocytoma and diffuse brainstem glioma: two challenges for the pediatric oncologist“ *Oncologist* 2004;9:197-206. Review, 15047924 [pubmed]
- [2] Cohen KJ,Pollack IF,Zhou T,Buxton A,Holmes EJ,Burger PC,Brat DJ,Rosenblum MK,Hamilton RL,Lavey RS,Heideman RL „, Temozolomide in the treatment of high-grade gliomas in children: a report from the Children's Oncology Group.“ *Neuro-oncology* 2011 Mar;13(3):317-23, 21339192 [pubmed]
- [3] Eyrich M „, Immuntherapie rezidivierter Gliome – ein individualisierter Therapieansatz“ *WIR - die Zeitschrift der Deutschen Leukämie-Forschungshilfe e.V. und der Deutschen Kinderkrebsstiftung* 2/2018, https://www.kinderkrebsstiftung.de/fileadmin/Redaktion/Zeitschrift_Wir/2018_2/Immuntherapie.pdf [uri]
- [4] Fleischhack G, Rutkowski S, Pfister SM, Pietsch T, Tippelt S, Warmuth-Metz M, Bison B, van Velthoven-Wurster V, Messing-Jünger M, Kortmann RD, Timmermann B, Slavc I, Witt O, Gnekow A, Hernáiz Driever P, Kramm C, Benesch M, Frühwald MC, Hasselblatt M, Müller HL, Sörensen N, Kordes U, Calaminus G. „, ZNS-Tumoren“ in: *Niemeyer C, Eggert A (Hrsg.): Pädiatrische Hämatologie und Onkologie. Springer-Verlag GmbH Deutschland, 2. vollständig überarbeitete Auflage* 2018: 359, 978-3-662-43685-1 [isbn]
- [5] Howe GR, Burch JD, Chiarelli AM, Risch HA, Choi BC „, An exploratory case-control study of brain tumors in children“ *Cancer Res* 1989;49(15):4349-52, 2743324 [pubmed]
- [6] Karremann M,Gielen GH,Hoffmann M,Wiese M,Colditz N,Warmuth-Metz M,Bison B,Claviez A,van Vuurden DG,von Bueren AO,Gessi M,Kühnle I,Hans VH,Benesch M,Sturm D,Kortmann RD,Waha A,Pietsch T,Kramm CM „, Diffuse high-grade gliomas with H3 K27M mutations carry a dismal prognosis independent of tumor location.“ *Neuro-oncology* 2018 Jan 10;20(1):123-131, 29016894 [pubmed]
- [7] Kramm C „, Die neue HIT-HGG-2013-Studie“ *WIR - Zeitschrift der Deutschen Kinderkrebsstiftung und der Deutschen Leukämie-Forschungshilfe e.V.* 3/17, https://www.kinderkrebsstiftung.de/fileadmin/Redaktion/Zeitschrift_Wir/2017_3/HIT.pdf [uri]
- [8] Kramm C „, Die HIT-HGG-Studiengruppe - Beratung und Protokolle für alle Behandlungssituationen bei hochmalignen Gliomen im Kindes- und Jugendalter“ *WIR - die Zeitschrift der Deutschen Leukämie-Forschungshilfe e.V. und der Deutschen Kinderkrebsstiftung* 1/2010, http://www.kinderkrebsstiftung.de/fileadmin/Redaktion/Zeitschrift_Wir/2010_1/WIR_1_10_klinik_01.pdf [uri]
- [9] Kramm C, Wolff J.E.A. „, Hochgradig maligne Gliome und Pongliome im Kindes- und Jugendalter“ *Interdisziplinäre Leitlinie der Deutschen Krebsgesellschaft und der Deutschen Gesellschaft für Pädiatrische Onkologie und Hämatologie* 2008, http://www.kinderkrebsstiftung.de/fileadmin/Redaktion/Leitlinien/2008/2008_01_HGG_Pongliome.pdf [uri]

www.awmf.org/uploads/tx_szleitlinien/025-024l_S1_Gliome_niedrigen_Malignitätsgrades_Kindesalter_Jugendalter_2013-06.pdf [uri]

- [10] Kramm C, Rausche U, Butenhoff S, Kühnöl C, Kunze C, Kortmann R, Wolff J, van Gool S „, Hochmaligne Gliome im Kindes- und Jugendalter“ *Monatsschr Kinderheilkd.* 2008, 156:1201-1207, 10.1007/s00112-008-1799-3 [doi]
- [11] Kramm CM, Wagner S, Van Gool S, Schmid H, Strater R, Gnekow A, Rutkowski S, Wolff JE „, Improved survival after gross total resection of malignant gliomas in pediatric patients from the HIT-GBM studies“ *Anticancer Res* 2006;26:3773-9, 17094400 [pubmed]
- [12] Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW „, The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.“ *Acta neuropathologica* 2016 Jun;131(6):803-20, 27157931 [pubmed]
- [13] MacDonald TJ, Aguilera D, Kramm CM. „, Treatment of high-grade glioma in children and adolescents.“ *Neuro Oncol* 2011, [Epub ahead of print], 21784756 [pubmed]
- [14] Ripperger T, Bielack SS, Borkhardt A, Brecht IB, Burkhardt B, Calaminus G, Debatin KM, Deubzer H, Dirksen U, Eckert C, Eggert A, Erlacher M, Fleischhack G, Frühwald MC, Gnekow A, Goehring G, Graf N, Hanenberg H, Hauer J, Hero B, Hettmer S, von Hoff K, Horstmann M, Hoyer J, Illig T, Kaatsch P, Kappler R, Kerl K, Klingebiel T, Kontny U, Kordes U, Körholz D, Koscielniak E, Kramm CM, Kuhlen M, Kulozik AE, Lamottke B, Leuschner I, Lohmann DR, Meinhardt A, Metzler M, Meyer LH, Moser O, Nathrath M, Niemeyer CM, Nustede R, Pajtler KW, Paret C, Rasche M, Reinhardt D, Rieß O, Russo A, Rutkowski S, Schlegelberger B, Schneider D, Schneppenheim R, Schrappe M, Schroeder C, von Schweinitz D, Simon T, Sparber-Sauer M, Spix C, Stanulla M, Steinemann D, Strahm B, Temming P, Thomay K, von Bueren AO, Vorwerk P, Witt O, Wlodarski M, Wössmann W, Zenker M, Zimmermann S, Pfister SM, Kratz CP „, Childhood cancer predisposition syndromes-A concise review and recommendations by the Cancer Predisposition Working Group of the Society for Pediatric Oncology and Hematology.“ *American journal of medical genetics. Part A* 2017;173(4):1017-1037, 28168833 [pubmed]
- [15] Rutkowski S, Trollmann R, Korinthenberg R, Warmuth-Metz M, Weckesser M, Krauss J, Pietsch T „, Leitsymptome und Diagnostik der ZNS-Tumoren im Kindes- und Jugendalter“ *Gemeinsame Leitlinie der Gesellschaft für Neuropädiatrie und der Gesellschaft für Pädiatrische Onkologie und Hämatologie* 2016, https://register.awmf.org/assets/guidelines/025-022l_S1_ZNS-Tumoren_Kinder_Jugendliche_2016-09-abgelaufen.pdf [uri]
- [16] Seidel C, von Bueren AO, Bojko S, Hoffmann M, Pietsch T, Gielen GH, Warmuth-Metz M, Bison B, Kortmann RD, Kramm CM „, Concurrent radiotherapy with temozolomide vs. concurrent radiotherapy with a cisplatin-based polychemotherapy regimen : Acute toxicity in pediatric high-grade glioma patients.“ *Strahlentherapie und Onkologie* 2018 Mar;194(3):215-224, 29022050 [pubmed]



- [17] Wagner S „, Therapie von hochgradig malignen Gliomen im Kindes- und Jugendalter“ *WIR Informationsschrift der Aktion für krebskranke Kinder e.V. (Bonn)* 2003,1:13, http://www.kinderkrebsstiftung.de/fileadmin/KKS/files/zeitschriftWIR/2003_1/behandlungsnetzwerk09.pdf [uri]
- [18] Wolff JE,Driever PH,Erdlenbruch B,Kortmann RD,Rutkowski S,Pietsch T,Parker C,Metz MW,Gnekow A,Kramm CM „, Intensive chemotherapy improves survival in pediatric high-grade glioma after gross total resection: results of the HIT-GBM-C protocol.“ *Cancer* 2010;116(3):705-12, 19957326 [pubmed]



Glossary

anamnesis		medical interview, a patient's history, development of signs of illness; the type, onset and course of the (current) symptoms as well as any risk factors (e.g. hereditary diseases) are evaluated during a medical interview.
astrocytoma		tumour of the central nervous system derived from astrocytes (a subtype of glial cells); belongs to the so-called gliomas
biopsy		removal of a tissue sample for subsequent (mainly microscopic) examination; this can be done, for example, by puncture with a hollow needle, with the use of special instruments (such as forceps, punching instruments, probes) or surgically with a scalpel.
blood group		hereditary, usually stable, structural characteristics (blood group antigens) of blood components (e.g. AB0 blood groups) located on the cell walls of blood and other tissue cells;
blood transfusion		transfer of blood (whole blood) or blood components (e.g. red blood cells or platelets) from a donor to a recipient.
brain		the part of the central nervous system (CNS) located in the head; the brain is protected by the skull and the meninges and consists mainly of nerve tissue.
brainstem		the section of the brain that forms the transition between the brain and the spinal cord; it controls vital functions, such as breathing, heart rate and blood pressure, and is responsible for important reflexes such as the blinking, swallowing or coughing reflex, lacrimation and saliva production. This is also where the roots of the cranial nerves are located.
cancer predisposition syndrome		genetic disorders that can include malformations and intellectual disability in addition to an increased risk of tumors; according to current knowledge, about 10% of childhood and adolescent cancers develop due to a known hereditary change or cancer predisposition syndrome. Cancer predisposition syndromes include Louis Bar syndrome (= ataxia telangiectatica), Beckwith-Wiedemann syndrome, Down syndrome, Hippel-Lindau syndrome, Li-Fraumeni syndrome, MEN syndrome, neurofibromatosis and WAGR syndrome. The familial form of retinoblastoma is also part of it.
central nervous system		comprises the brain and spinal cord and is separated from the so-called peripheral nervous system; as a central organ



	<p>of integration, coordination and regulation, it serves to process external sensory impressions as well as stimuli produced by the organism itself.</p>
cerebellum	<p>part of the brain that is located in the posterior fossa of the skull, between the cerebrum and the brainstem; it is mostly responsible for the coordination of all body movements and also for maintaining balance.</p>
cerebrospinal fluid	<p>fluid produced by cells of the cerebral ventricles; it floats around the brain and spinal cord to protect them from injury and provide them with nutrients.</p>
cerebrum	<p>largest and most highly developed section of the brain; it consists of two hemispheres connected by a thick bundle of nerves (corpus callosum). Each hemisphere of the brain is specialized on specific tasks. The outermost layer of the cerebrum, the cerebral cortex, houses the ability to learn, speak and think, as well as consciousness and memory, amongst other things. This is also where the processing centres for information from the sensory organs (e.g. eyes, ears) are located.</p>
chemotherapy	<p>here: use of drugs (chemotherapeutic agents, cytostatics) for the specific inhibition of tumor cells in the organism</p>
CNS tumour	<p>tumour of the central nervous system; a primary CNS tumour is a solid tumour that originates from brain or spinal cord tissue. Secondary CNS tumours are metastases of tumours located in other organs or tissues.</p>
computed tomography	<p>imaging, X-ray diagnostic procedure; it produces an image by computer-controlled evaluation of a large number of X-rays from different directions. This makes it possible to produce sliced images of body parts (tomograms, transverse or longitudinal sections of the human body)</p>
diencephalon	<p>vital part of the brain with function for numerous life processes; it connects to the brainstem towards the cerebrum and consists of functionally different sections. The "thalamus", for example, decides which sensory impressions should penetrate into consciousness and are to be sent to the appropriate processing centers. The "hypothalamus" serves as a mediator between the hormonal and nervous systems and controls, among other things, important metabolic processes (e.g. heat and water balance, carbohydrate, fat, protein metabolism, blood pressure). Together with the pituitary gland, it regulates the activity of subordinate</p>



	<p>glands. Other parts of the diencephalon are responsible for muscle activities and for controlling the day-night rhythm.</p>
echocardiography	<p>ultrasound examination of the heart to check its performance (cardiac function); the position or structure of the heart valves and walls, the wall thickness of the heart muscle, the size of the heart and the ejected blood volume (pumping function of the heart) are examined and assessed, among other things.</p>
electrocardiography	<p>method of measuring the electrical activity of the heart</p>
electroencephalography	<p>method of recording the electrical activity of the brain; the electroencephalogram (also abbreviated EEG) is the graphical representation of this electrical brain activity. Its evaluation can provide evidence of brain dysfunctions.</p>
epilepsy	<p>a condition associated with seizures, which is caused by dysfunction of the brain (leading to recurrent bursts of uncontrolled electrical activities between nerve cells in the brain), which can be triggered by various factors. Treatment is usually with antiepileptic drugs.</p>
evoked potentials	<p>examination method that can be used to test the conductivity and thus the functionality of nerve pathways; the principle is based on a controlled stimulation of a sensory organ or peripheral nerve (e.g. eyes, hearing, sense of touch) and the verification of the stimulus response (electrical potential) triggered by this in processing regions of the central nervous system.</p>
fontanelle	<p>soft spot on an infant's head, due to the bony plates not having connected yet; the final closure usually occurs before the age of two.</p>
genetic	<p>concerning the (level of) inheritance or genes; inherited</p>
glial cells	<p>component of the nerve tissue; glial cells primarily form the supporting, enveloping and nourishing tissue of the nervous system.</p>
glioblastoma	<p>a highly malignant, rapidly growing tumour of the central nervous system belonging to the glioma group; glioblastoma originates from the nerve support tissue, the glial cells. It is classified as a grade IV tumour according to the WHO classification.</p>
gray	<p>unit of measurement for the dose of energy caused by ionising radiation (e.g. in the context of radiotherapy) and absorbed by a given mass (kilogram of body weight)</p>



histological	concerning the tissues of the body; in a histological (fine tissue) examination, tissue samples are examined under the microscope after special preparation (preparation of tissue sections and use of certain staining techniques).
hydrocephalus	medical term for abnormal buildup of cerebrospinal fluid in the cavities (ventricles) in the brain; it is caused by a dilation of the brain's ventricles due to various causes.
imaging	diagnostic procedures generating images of the inside of the body, such as ultrasound and X-ray examination, computed tomography, magnetic resonance imaging, and scintigraphy
leukaemia	malignant disease of the blood forming (haematopoietic) system and the most common cancer in children and adolescents (about 33%); depending on the origin of the malignant cells, a distinction is made between lymphoblastic and myeloid leukaemias. Depending on the course of the disease (fast or slow), a distinction is made between acute and chronic leukaemias.
Li-Fraumeni syndrome	cancer predisposition syndrome characterized by the increased occurrence of various solid tumours within a family; in childhood and adolescence, tumours of the adrenal glands, as well as soft tissue sarcomas, leukaemias and CNS tumours are most commonly observed, in adulthood mainly bone tumours (osteosarcomas), breast cancer and lung tumours. In most cases, there is a change (mutation) of the so-called tumour suppressor gene TP-53 (protein p53).
lumbar puncture	puncture of the spinal canal in the lumbar spine, e.g. to remove cerebrospinal fluid (CSF) or for the purpose of administering medication (so-called intrathecal treatment); in the case of cancer, a sample and examination of cerebrospinal fluid can be used to detect malignant cells; in the case of increased intracranial pressure due to a CNS tumour, cerebrospinal fluid removal (CSF) is also used to relieve pressure.
macrocephalus	large head, which can be caused by a hydrocephalus (hydrocephalus) in a child with unclosed fontanelles, but also by a large tumour or both
magnetic resonance imaging	diagnostic imaging method; very precise, radiation-free examination method for the visualization of structures inside the body; with the help of magnetic fields, cross-sectional images



of the body are generated, which usually allow a very good assessment of the organs and many organ changes.

midbrain	part of the brainstem; adjacent to the diencephalon at the top and the bridge at the bottom, the latter of which is also part of the brainstem. In the midbrain, there are important pathways that ascend and descend between the brain and the spinal cord. The midbrain is also home to the eye muscle nerves (cranial nerves III and IV) and to the nerve cell nuclei for certain muscle activities (e.g. of the face and neck).
molecular	at the level of molecules
MRI	abbreviation for magnetic resonance imaging, a very precise, radiation-free examination method for imaging structures inside the body
neurological	referring to the function of the nervous system / nerve tissue
neurosurgery	a branch of surgery that includes parts of the diagnosis and surgical treatment of diseases of the nervous system
operability	feasibility of surgery as a treatment option; whether a patient is operated depends on their clinical condition and on whether the procedure is an appropriate and effective form of treatment in the respective case (indication). The operability of a tumour particularly depends on its location in the body and its growth behaviour.
ophthalmological	referring to the eye or eye care (ophthalmology)
paediatric oncologist	paediatrician who is specialized on the management of children and adolescents with cancer
palliative therapy	anti-cancer therapy that is primarily aimed at maintaining or improving the quality of life; palliative therapy becomes relevant when a patient can no longer be cured. In contrast, curative therapy is primarily aimed at healing the patient.
physical examination	an important part of diagnostic examinations; includes palpation and listening to certain body organs as well as testing reflexes to obtain indications of the nature or course of a disease.
prognosis	prediction of the course and outcome of a disease / prospect of recovery
prognostic factors	factors that allow an approximate assessment of the further course of the disease (i.e. the prognosis);



radiation	controlled use of ionizing (high-energy) radiation for the treatment of malignant diseases
radiation therapy	controlled use of ionizing (high-energy) radiation for the treatment of malignant diseases
radiologist	a physician specialized in diagnostic imaging and radiotherapy
randomisation	(statistical) random distribution of patients to treatment and control groups in a study; the strict random distribution is intended to eliminate systematic errors in the evaluation of therapy studies.
recurrence	relapse, recurrence of a disease after recovery
retinoblastoma	a rare malignant tumour of the retina that occurs almost exclusively in children; there are hereditary and non-hereditary forms of the disease. Either one or both eyes can be affected (unilateral or bilateral retinoblastoma). In very rare cases, hereditary retinoblastoma can also occur together with a brain tumour (e.g., pineoblastoma); in this case, it is called trilateral retinoblastoma.
seizures	uncontrolled electrical activity between nerve cells in the brain; a distinction is made between focal and generalized seizures. Focal seizures are limited to a specific area of the brain; depending on the area of the brain, the symptoms vary: e.g. twitching of one side of the body, an arm or a leg. Generalized seizures spread over large areas of the brain and lead, for example, to twitching of the limbs, sudden absence and loss of consciousness.
solid tumour	solid, localized increase of the body's own tissue; solid tumours can originate from various tissues and can be benign or malignant; only the malignant ones are considered as cancers. Solid tumours include all cancers that do not affect the haematopoietic or lymphatic system. The latter are systemic malignancies. The most common solid tumours in childhood and adolescence are brain tumours, followed by neuroblastoma and soft tissue sarcomas.
spinal cord	part of the central nervous system; its main function is to transmit messages between the brain and other organs of the body. The spinal cord is protectively enveloped by the three spinal cord membranes and the bony spinal canal.
symptom	sign of illness
therapy optimising trial	a controlled clinical trial (study) that aims to provide the best possible treatment for patients and at the same time to improve and develop treatment options; therapy optimisation is aimed not



	only at improving the chances of recovery, but also at limiting treatment-related side effects and long-term effects.
tumour	groups of abnormal cells forming a growing lump, both benign and malignant
Turcot syndrome	rare hereditary disease characterized by the appearance of tumours, for example, adenomas in the gastrointestinal tract and brain tumours (medulloblastomas, glioblastomas)
WHO classification	international guideline developed by the World Health Organization (WHO) for classification, diagnosis and differentiation/grading of (malignant) diseases